Description
Bisindolylmaleimide III was developed as a protein kinase C (PKC) inhibitor with structural similarity to the nonspecific PKC inhibitor staurosporine. At 1 μM, bisindolylmaleimide III inhibits 93% of PKCα kinase activity and also inhibits many other protein kinases including, S6K1, MAPKAP-
K
1, RSK2 and MSK1 with similar potency. Additionally, it inhibits PDK1, an important kinase in the insulin signaling pathway, with an IC
50 value of 3.8 μM.
Uses
Bisindolylmaleimide III is a protein kinase C inhibitor and was also shown to exhibit inhibitory activities towards PDK1, an important kinase in the insulin signaling pathway,
Definition
ChEBI: Bisindolylmaleimide III is a member of maleimides and a member of indoles. It has a role as an EC 2.7.11.13 (protein kinase C) inhibitor. It is functionally related to a maleimide.
References
[1] PETER D. DAVIS. Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides[J]. Journal of Medicinal Chemistry, 1992, 35 1: 177-184. DOI:
10.1021/jm00079a024[2] DAVID SORIANO-CASTELL Pamela M Antonio Currais. Defining a pharmacological inhibitor fingerprint for oxytosis/ferroptosis[J]. Free Radical Biology and Medicine, 2021, 171: Pages 219-231. DOI:
10.1016/j.freeradbiomed.2021.05.023
